CJC-1295 (No DAC/Mod GRF 1-29)

Common side effects:

• Injection site reactions including redness or swelling
• Transient flushing of the face or skin
• Mild water retention or edema in extremities
• Temporary numbness or tingling (paresthesia)
• Headaches shortly after administration

Rare or serious side effects:

• Insulin resistance with prolonged use
• Carpal tunnel syndrome due to fluid retention
• Acromegaly-like symptoms under excessive dosing
• Pituitary gland overstimulation or hyperplasia

Receptor binding and activation initiate the primary mechanism of the CJC-1295 (No DAC/Mod GRF 1-29) peptide. It selectively binds to the growth hormone-releasing hormone receptor (GHRHR) located on the anterior pituitary gland. This binding triggers a cAMP-dependent intracellular signaling pathway that stimulates the synthesis and secretion of endogenous growth hormone. Unlike synthetic secretagogues that cause a continuous hormone bleed, this modified peptide preserves the natural pulsatile release of growth hormone. Enzymatic resistance is achieved through specific amino acid substitutions at positions 2, 8, 15, and 27 of the original GRF 1-29 sequence. These modifications protect the peptide chain from rapid degradation by dipeptidyl peptidase-4 (DPP-IV) and other blood plasma enzymes. Consequently, the half-life is extended from mere minutes to approximately 30 minutes, allowing for a more sustained therapeutic window. This optimized pharmacokinetic profile maximizes CJC-1295 (No DAC/Mod GRF 1-29) benefits while minimizing the risk of receptor downregulation.

Discovery and structural evolution of Modified GRF 1-29 emerged from efforts to improve the clinical viability of natural growth hormone-releasing hormone. Researchers identified that the first 29 amino acids of the 44-amino-acid GHRH sequence retained full biological activity, leading to the creation of Sermorelin. To overcome Sermorelin's extremely short half-life, scientists introduced four specific amino acid substitutions, creating what is now known as Mod GRF 1-29. This compound is frequently, though inaccurately, referred to as CJC-1295 without the Drug Affinity Complex (DAC). Regulatory and research status currently classifies this compound strictly as a research chemical rather than an FDA-approved therapeutic. While the DAC-bound version was developed by ConjuChem to bind with serum albumin for a multi-day half-life, the non-DAC version remains popular in clinical studies requiring short-acting pulsatile stimulation. Ongoing investigations continue to evaluate CJC-1295 (No DAC/Mod GRF 1-29) side effects and long-term safety in anti-aging and metabolic research contexts.